Systemic and topical drugs for the prevention of HIV infection: Antiretroviral pre-exposure prophylaxis

Annual Review of Medicine

Volumn 64, Issue , 2013, Pages 219-232

  Baeten, Jared ^a   Celum, Connie ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

emtricitabine; HIV transmission; men who have sex with men; tenofovir; women

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR DISOPROXIL;

DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHESIS; KIDNEY DISEASE; MALE HOMOSEXUAL; NONHUMAN; PATIENT COMPLIANCE; PRE EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ANTI-HIV AGENTS; DRUG ADMINISTRATION ROUTES; HIV; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; MEDICATION ADHERENCE; TREATMENT OUTCOME;

EID: 84873034364     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-050911-163701     Document Type: Review

References (49)

1. Attia S, Egger M, Muller M, et al. 2009. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 23:1397-404
2. Donnell D, Baeten JM, Kiarie J, et al. 2010. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 375:2092-98
3. Cohen MS, Chen YQ, McCauley M, et al. 2011. Prevention of HIV-1 infection with early antiretroviral therapy. N. Engl. J. Med. 365:493-505
4. YouleM, Wainberg MA. 2003. Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS 17:937-38
5. Garcia-Lerma JG, Otten RA, Qari SH, et al. 2008. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med. 5:e28
6. Parikh UM, Dobard C, Sharma S, et al. 2009. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J. Virol. 83:10358-65
7. Subbarao S, Otten RA, Ramos A, et al. 2006. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J. Infect. Dis. 194:904-11
8. Cong ME, Youngpairoj AS, Zheng Q, et al. 2011. Protection against rectal transmission of an emtricitabine-resistant simian/human immunodeficiency virus SHIV162p3M184V mutant by intermittent prophylaxis with Truvada. J. Virol. 85:7933-36
9. Chasela CS, Hudgens MG, Jamieson DJ, et al. 2010. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N. Engl. J. Med. 362:2271-81
10. Mofenson LM. 2010. Protecting the next generation-eliminating perinatal HIV-1 infection. N. Engl. J. Med. 362:2316-18
11. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. 2010. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 329:1168-74
12. Abdool Karim SS, Kashuba AD, Werner L, et al. 2011. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet 378:279-81
13. Andrei G, Lisco A, Vanpouille C, et al. 2011. Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe 10:379-89
14. Hendrix C, Minnis A, Guddera V, et al. 2011. MTN-001: a phase 2 cross-over study of daily oral and vaginal TFV in healthy, sexually active women results in significantly different product acceptability and vaginal tissue drug concentrations. Presented at Conf. Retroviruses and Opportunistic Infections, 18th, Feb. 27-Mar. 2, Boston, MA
15. Follow-on Africa Consortium for Tenofovir Studies. 2010. FACTS 001-tenofovir gel study. http://www. facts-consortium.co.za/?page-id=83
16. Grant RM, Lama JR, Anderson PL, et al. 2010. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N. Engl. J. Med. 363:2587-99
17. Anderson P, Lama J, Buchbinder S, et al. 2011. Interpreting detection rates of intracellular FTC-TP and TFVDP: the iPrEx trial. Presented at Conf. Retroviruses and Opportunistic Infections, 18th, Feb. 27-Mar. 2, Boston, MA
18. Van Damme L, Corneli A, Ahmed K, et al. 2012. Preexposure prophylaxis for HIV infection among African women. N. Engl. J. Med. 367:411-22
19. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. 2012. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N. Engl. J. Med. 367:423-34
20. Mujugira A, Baeten JM, Donnell D, et al. 2011. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS ONE 6:e25828
21. Baeten JM, Donnell D, Ndase P, et al. 2012. Antiviral prophylaxis for HIV prevention in heterosexual men and women. N. Engl. J. Med. 367:399-410
22. BangsbergD, Haberer J, Psaros C, et al. 2012. High adherence and high effectiveness observed in HIV discordant couples: Partners PrEP Study, adherence monitoring and counseling substudy. Presented at Conf. Retroviruses and Opportunistic Infections, 19th, Mar. 5-8, Seattle, WA
23. Donnell D, Baeten J, Hendrix C, et al. 2012. Tenofovir disoproxil fumarate drug levels indicate PrEP use is strongly correlated with HIV-1 protective effects: Kenya and Uganda. Presented at Conf. Retroviruses and Opportunistic Infections, 19th, Mar. 5-8, Seattle, WA
24. National Institute ofAllergy and Infectious Diseases (NIAID). 2011.NIHmodifies "VOICE"HIV prevention study in women. http://www.nih.gov/news/health/sep2011/niaid-28.htm
25. National Institute of Allergy and Infectious Diseases (NIAID). 2011. NIH discontinues tenofovir vaginal gel in 'Voice' HIV prevention study. http://www.nih.gov/news/health/nov2011/niaid-25.htm
26. Martin M, Vanichseni S, Suntharasamai P, et al. 2011. Enrollment characteristics and risk behaviors of injection drug users participating in the Bangkok Tenofovir Study, Thailand. PLoS ONE 6:e25127
27. Gray RH, Kigozi G, Serwadda D, et al. 2007. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369:657-66
28. Bailey RC, Moses S, Parker CB, et al. 2007. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369:643-56
29. Auvert B, Taljaard D, Lagarde E, et al. 2005. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 trial. PLoS Med. 2:e298
30. Anderson P, Meditz A, Zheng J-H, et al. 2012. Cellular pharmacology of tenofovir and emtricitabine in blood, rectal, and cervical cells from HIV- volunteers. Presented at Conf. Retroviruses and Opportunistic Infections, 19th, Mar. 5-8, Seattle, WA
31. Patterson KB, Prince HA, Kraft E, et al. 2011. Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci. Transl. Med. 3:112re4
32. HeffronR, Donnell D, Rees H, et al. 2012. Use of hormonal contraceptives and risk ofHIV-1 transmission: a prospective cohort study. Lancet Inf. Dis. 12:19-26
33. Low N, Chersich MF, Schmidlin K, et al. 2011. Intravaginal practices, bacterial vaginosis, and HIV infection in women: individual participant data meta-analysis. PLoS Med. 8:e1000416
34. Liu A, Vittinghoff E, Irby R, et al. 2011. BMD loss in HIV- men participating in a TDF PrEP clinical trial in San Francisco. Presented at Conf. Retroviruses and Opportunistic Infections, 18th, Feb. 27-Mar. 2, Boston, MA
35. Mugo N, Celum C, Donnell D, et al. 2012. Pregnancy incidence and birth outcomes in a clinical trial of PrEP: Uganda and Kenya. Presented at Conf. Retroviruses and Opportunistic Infections, 19th, Mar. 5-8, Seattle, WA
36. Antiretroviral Pregnancy Registry. 2011. Interim report, 1 January 1989 through 31 July 2011. http://www. apregistry.com/forms/interim-report.pdf
37. Liegler T, Abdel-Mohsen M, Atchison R, et al. 2011. Drug resistance and minor drug resistant variants in iPrEx. Presented at Conf. Retroviruses and Opportunistic Infections, 18th, Feb. 27-Mar. 2, Boston, MA
38. Cassell MM, Halperin DT, Shelton JD, Stanton D. 2006. Risk compensation: the Achilles' heel of innovations in HIV prevention? BMJ 332:605-7
39. Ware N, Wyatt M, Haberer J, et al. 2012. What's love got to do with it? A theory of adherence to oncedaily oral pre-exposure prophylaxis (PrEP) for HIV prevention derived from qualitative data among HIV serodiscordant couples. J. Acquir. Immune Defic. Syndr. 59:463-68
40. Curran K, Baeten JM, Coates TJ, et al. 2012. HIV-1 prevention for HIV-1 serodiscordant couples. Curr. HIV/AIDS Rep. 9:160-70
41. Hallett TB, Baeten JM, Heffron R, et al. 2011. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med. 8:e1001123
42. Juusola JL, Brandeau ML, Owens DK, Bendavid E. 2012. The cost-effectiveness of preexposure prophylaxis for HIV prevention in the United States in men who have sex with men. Ann. Int. Med. 156:541-50
43. Walensky RP, Park JE, Wood R, et al. 2012. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin. Infect. Dis. 54:1504-13
44. HIV Prevention Trials Network. 2011. HPTN 067-the ADAPT Study: a phase II, randomized, open-label, pharmacokinetic and behavioral study of the use of intermittent oral emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis (PrEP). http://www.hptn.org/research-studies/hptn067.asp
45. Matthews LT, Baeten JM, Celum C, et al. 2010. Periconception pre-exposure prophylaxis to preventHIV transmission: benefits, risks, and challenges to implementation. AIDS 24:1975-82
46. Romano J, Variano B, Coplan P, et al. 2009. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res. Hum. Retrovir. 25:483-88
47. Veazey R, Ketas T, Dufour J, et al. 2010. Protection of rhesus macaques from vaginal infection by maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. Presented at Conf. Retroviruses and Opportunistic Infections, 17th, Feb. 16-19, San Francisco, CA
48. Dobard C, Sharma S, Parikh U, et al. 2011. High protection against vaginal infection in macaques by PEP with gel containing RAL. Presented at Conf. Retroviruses and Opportunistic Infections, 18th, Feb. 27-Mar. 2, Boston, MA
49. Jackson A, Else L, Tjia J, et al. 2012. Rilpavirine-LA formulation: pharmacokinetics in plasma, genital tract in HIV- females and rectum in males. Presented at Conf. Retroviruses and Opportunistic Infections, 19th, Mar. 5-8, Seattle, WA